EP Patent

EP2580225A1 — Crystalline form of benzylbenzene sglt2 inhibitor

Assigned to Theracos Sub LLC · Expires 2013-04-17 · 13y expired

What this patent protects

Crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2 are disclosed. Pharmaceutical compositions, methods for preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination w…

USPTO Abstract

Crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2 are disclosed. Pharmaceutical compositions, methods for preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
EP2580225A1
Jurisdiction
EP
Classification
—
Expires
2013-04-17
Drug substance claim
No
Drug product claim
No
Assignee
Theracos Sub LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.